DYAI — Dyadic International Share News
0.000.00%
Last trade - 00:00- $15.99m
- $17.91m
- $3.09m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:56 AM
Dyadic shares soar after license announcement with Sorrento
Brief: Dyadic And Sorrento Announce Binding Term Sheet To License Dyadic’S Lead Covid-19 Vaccine Candidate “Dyai-100” And C1 Technology For Protein-Based Coronavirus Vaccines And Therapeutics
Dyadic International Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Dyadic Announces Technology Transfer And Licensing Agreement With Rubic Consortium
Brief: Dyadic International Says Unit Entered Into Amendment To Master Services Agreement With CR2O
Brief: Dyadic Announces Development Of Covid-19 Vaccine In India
Brief: Dyadic International Says Advancing Proprietary Owned Covid-19 Vaccine Candidate, Dyai-100, Towards Human Clinical Trial
Brief: Dyadic And Medytox To Develop Vaccines Against Covid-19 Variants
U.S. STOCKS ON THE MOVE-Tesla, Applied Materials, SVB Financial, Support.Com
U.S. STOCKS ON THE MOVE-Tesla, General Motors, Support.com, Kansas City Southern, RLX Technology
Dyadic: Rises on expanding partnership to make COVID-19 vaccines for variants
Brief: Dyadic And Medytox To Develop Vaccines Against COVID-19 Variants
Brief: Dyadic - Feb. 16 Presentation Had Discussion Of Plan To Initiate Potential Phase I Clinical Study Related To Co's Recombinant Sars-Cov-2 Rbd Antigen
Brief: Dyadic And TurtleTree Scientific Enter Strategic Partnership
Brief: Dyadic International Inc - Patrick Lucy Has Been Appointed To Board
Brief: Dyadic International Reports Qtrly Loss Per Share Of $0.09
Brief: Dyadic International Inc Files For Stock Shelf Of Upto $50 Mln
Brief: Dyadic International Posts Quarterly Loss Per Share Of $0.10